ReviewFrontiers in medicine2022
Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Impact of anti-VEGF therapy on choroidal thickness in patients with retinal vein occlusion: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Long term efficacy and safety profile of dexamethasone intravitreal implant in retinal vein occlusions: a systematic review.Frontiers in medicine · 2024Pooled it
- Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study.Reviews on recent clinical trials · 2024Trial
- Central Retinal Vein Occlusion in the Absence of Conventional Risk Factors Associated With Breast Carcinoma: A Case Report.Clinical case reports · 2026Article
- Switching anti-VEGF agents does not improve visual outcomes in branch retinal vein occlusion-related macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Optimal Treatment of Retinal Vein Occlusion: An Updated Canadian Review and Recommendations.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Impact of Comorbid Hypertension and Diabetes on Anti-VEGF Treatment Outcomes in Macular Edema.Journal of ophthalmology · 2026Article
- Intravitreal exposure to the SARS-CoV-2 spike protein is associated with aggravated retinal lesions in a murine model of central retinal vein occlusion.Frontiers in medicine · 2026Article
- Efficacy and Safety of Ranibizumab Combined with Dexamethasone Intravitreal Implant Sequential Therapy for Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusion.Drug design, development and therapy · 2026Article
- Triglyceride-glucose index as a potential biomarker for predicting retinal vein occlusion.Scientific reports · 2025Article
- Recent advances in the treatment of retinal vein occlusion with traditional Chinese medicine.International ophthalmology · 2025Review
- Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.Materials today. Bio · 2025Review
- The Diagnosis and Treatment of Branch Retinal Vein Occlusions: An Update.Biomedicines · 2025Review
- Global trends in retinal vein occlusion studies from 2004 to 2023: a bibliometric analysis.International journal of ophthalmology · 2025Article
- Elevated triglyceride-glucose index increases risk in patients with retinal vein occlusion.Frontiers in medicine · 2025Article
- Utility of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in individuals with retinal vein occlusion.Frontiers in cardiovascular medicine · 2025Article
- Serologic parameters in young patients with retinal vein occlusion treated with anti-vascular endothelial growth factor.International journal of ophthalmology · 2025Article
- Causal Associations of Smoking, Alcohol, Obesity, Sedentary Behavior, Hypertension, and Hyperglycemia With Retinal Vein Occlusion: A Mendelian Randomization Study.Current genomics · 2025Article
- "ArmedFrontiers in cell and developmental biology · 2025Review
- Faricimab for retinal vein occlusion: a review of current evidence and future perspectives.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal vein occlusion (RVO) is the second most prevalent retinal disease. Despite this, the pathogenic mechanisms and risk factors are not entirely clear. In this article, we review recent publications on the classification, pathogenesis, risk factors, ischemic changes, cytokines, and vital complications of RVO. Risk factors and cytokines are important for exploring the mechanisms and new treatment targets. Furthermore, risk factors are interrelated, making RVO mechanisms more complex. Cytokines act as powerful mediators of pathological conditions, such as inflammation, neovascularization, and macular edema. This review aims to summarize the updated knowledge on risk factors, cytokines of RVO and signaling in order to provide valuable insight on managing the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.